MedPath

Differential Effects of Remimazolam and Propofol on Dynamic Cerebral Autoregulation During General Anesthesia

Not Applicable
Recruiting
Conditions
General Anesthesia
Laparoscopic Cholecystectomy
Remimazolam
Propofol
Dynamic Cerebral Autoregulation
Interventions
Registration Number
NCT05533580
Lead Sponsor
Second Affiliated Hospital of Nanchang University
Brief Summary

Cerebral autoregulation (CA) is the property of the cerebral vascular bed to maintain cerebral perfusion in the presence of changes in blood pressure. In the case of anesthesia, altered cerebral autoregulation, including altered carbon dioxide and hemodilution, can impair physiological changes in the body and lead to poor postoperative prognosis. As a novel ultra-short-acting benzodiazepines drugs, remimazolam has been accepted for induction and maintenance of clinical anesthesia. Compared to the traditional benzodiazepines drugs, remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. Our study aimed to investigate the different effects of remimazolam and propofol on dynamic cerebral blood flow autoregulation function during general anesthesia.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  1. Age 18-60 years, gender not limited
  2. Patients proposed to undergo elective laparoscopic cholecystectomy under general anesthesia, with an expected operative length of approximately 1h~2h
  3. Good penetration of the temporal window.
  4. ASA anesthesia classification grade I to II.
  5. can communicate effectively with the physician.
  6. Patients were aware of and voluntarily signed the informed consent form.
Read More
Exclusion Criteria
  1. Relative contraindications to general anesthesia: patients with severe heart and lung function diseases.
  2. History of syncope, and dizziness.
  3. Patients with a history of psychiatric disorders, neurological disorders, drug abuse, or drug addiction
  4. Patients with cerebrovascular or carotid artery lesions;
  5. Those who are unable to cooperate in completing the test
  6. Persons who have taken benzodiazepines intermittently in the last three months.
  7. Those with known allergies or allergies to the test drug.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Propofol groupPropofol1. Induction of anesthesia Slowly injects propofol 2-4 mg/kg (about 1 min) until loss of consciousness (LoC), allowing additional propofol (0.5 mg/kg each time) if sedation is insufficient. after LoC, intravenous sufentanil 0.3 \~0.5ug/kg and cisatracurium besylate 0.1 mg/kg. after sufficient muscle relaxation and blood circulation stabilization, the tracheal tube was inserted under the sliding scope. 2. Maintenance of anesthesia propofol 4\~10mg/kg/h and remifentanil 0.1\~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besylate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 10 %.
Remimazolam groupRemimazolam1. Induction of anesthesia Slowly injects remimazolam 0.4-0.6 mg/kg (about 1 minute) until loss of consciousness (LoC), if the degree of sedation is insufficient, additional remimazolam (0.05 mg/kg each time) is allowed. After the LoC, intravenous sufentanil 0.3 \~0.5ug/kg and cisatracurium besylate 0.1 mg/kg are injected intravenously. After the muscles are sufficiently relaxed and blood circulation is stable, the tracheal tube is inserted under a glide scope. 2. Maintenance of anesthesia remimazolam 0.4\~1.2 mg/kg/h and remifentanil 0.1\~0.3 ug/kg/min are injected intravenously to maintain sedation and assistant analgesia, and cisatracurium besylate 0.02 mg/kg is allowed to add as appropriate. During the operation, the dose of anesthetic drugs is adjusted so that the fluctuation of heart rate and blood pressure did not exceed 10 %.
Primary Outcome Measures
NameTimeMethod
Differences in dynamic cerebral blood flow autoregulationFrom the time the patient enters the operating room to the time they leave the operating room, one and a half hours on average.

Comparison of the consistency, gain and phase of the transfer function parameters in the frequency range of 0.02-0.07 Hz, 0.07-0.2 Hz and 0.2-0.5 Hz for the propofol and rimazolam groups, respectively.

Secondary Outcome Measures
NameTimeMethod
diastolic pressureUp to 5 hours including preoperative, intraoperative, and postoperative periods

Indicators related to perioperative hemodynamics

heart rateUp to 5 hours including preoperative, intraoperative, and postoperative periods

Indicators related to perioperative hemodynamics

systolic pressureUp to 5 hours including preoperative, intraoperative, and postoperative periods

Indicators related to perioperative hemodynamics

mean pressureUp to 5 hours including preoperative, intraoperative, and postoperative periods

Indicators related to perioperative hemodynamics

pulseUp to 5 hours including preoperative, intraoperative, and postoperative periods

Indicators related to perioperative hemodynamics

Recovery timesUp to 30 minutes after operation

The period from discontinuation of anesthetic drugs to the recovery of the patient's self-consciousness and can respond correctly to external stimuli. All the patients can be allowed to leave the post-anesthesia care unit after Aldrete ≥ 9. Delayed awakening is defined as failure to achieve Aldrete ≥ 9 more than 30 minutes after surgery.

ComplicationDuring the perioperative period

All the perioperative complications are recorded.

Trial Locations

Locations (1)

the Second Affiliated Hospital of Nanchang University, Nanchang University

🇨🇳

Nanchang, Jiangxi, China

© Copyright 2025. All Rights Reserved by MedPath